Males with lupus nephritis had higher all-cause mortality and proportion of infection-related death compared to females.

There are no significant differences in outcomes post-AMI in patients with systemic lupus erythematosus vs the general population.

The Global Systemic Lupus Erythematosus Treatment Market is valued approximately at USD 2.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.64% over the forecast ...

Preconception predictors of adverse pregnancy outcomes among women with SLE include previous lupus nephritis, chronic hypertension, SLE disease activity, and APS.

Current treatment options for systemic lupus erythematosus (SLE) consists of glucocorticoids, antimalarials, immunosuppressives, and a few biologics, approved or of 'off-label'. Through judicious ...

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

SLE: Systemic lupus erythematosus. Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life.

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Cullinan Management (CGEM – Research Report), retaining the price target of ...

Investing in Cabaletta Bio for potential high returns on innovative CAR-T therapies despite volatility and risk. Click here ...

ANAs are proteins produced by the immune system that mistakenly target the body's own cells, leading to tissue damage and ...